Clinical stage

Patent protected Medtech company

The ScienceAbout us

Eradicate Glioblastoma –

Starting Where Surgery Ends

Ambusol is pioneering therapies to eliminate residual glioblastoma (GBM) cells after surgery – and give patients new hope.

Our Mission: Eradicate Glioblastoma – Starting Where Surgery Ends.


Ambusol is a clinical-stage cancer therapeutics company pioneering a patented approach to treat post-surgical Stage IV glioblastoma (GBM). Our mission is to eradicate residual cancer cells in the surgical margins and significantly improve patient outcome.

With 50 years of research from Uppsala Academic Hospital, we strive to offer groundbreaking treatment options for glioblastoma (GBM) that aim not only to extend patients’ lives but also to improve their quality of life. Through innovative approaches and a deep understanding of the complexity of the disease, we work tirelessly to create treatments that not only combat the disease but also promote well-being and recovery in our patients.

Our treatment against GBM

GBM therapy offers customized care and hope for a brighter future against glioblastoma (GBM).

Innovation

We are pushing the boundaries of medical innovation.

Hope

We offer hope and healing for you and your loved ones.

Commitment

We are committed to every step of the journey to better treatment.

Our story

Founded by the esteemed Professor Gunnar Ronquist, Ambusol emerged with an ambitious mission: to revolutionize the treatment of glioblastoma (GBM) and join the relentless battle against cancer. Our unwavering passion and dedication lie in developing a transformative therapy for GBM, relentlessly pursuing a deeper understanding of this formidable disease, and refining its management strategies. Through relentless innovation and unwavering research, we strive to offer hope and a brighter future for all those grappling with this debilitating illness.

Our unwavering commitment to developing effective therapies and our unwavering focus on driving meaningful change in the fight against GBM propel us to continuously challenge the frontiers of medical science and technology. We are driven by the profound belief that GBM, despite its formidable nature, can be effectively treated, and that our efforts can make a tangible difference in the lives of patients and their families.

Targeting Amino Acid Transporters

Our lead compound is a non-physiological amino acid that selectively induces cytolysis (cell death) in highly malignant glioma cells by exploiting their metabolic vulnerabilities.

  • GBM cells take up the amino acid at a rate four times higher than healthy brain cells.
  • This excessive uptake causes osmotic imbalance, leading to water influx, cell swelling, and eventual tumor cell rupture.
  • Healthy glial cells have low uptake capacity and are not affected, supporting a favorable safety profile.

Clearance of the Tumor Microenvironment (TME)

The TME is a critical driver of GBM progression, therapy resistance, and recurrence. One of its key components is extracellular vesicles (EVs), tiny particles that carry oncogenic proteins, RNA, and DNA to other cells, promoting tumor growth and immune evasion.

Our approach aims to disrupt this intercellular communication by:

  • Clearing EVs and other pro-tumor factors from the surgical cavity
  • Interrupting signaling pathways that support tumor proliferation, angiogenesis, metabolic reprogramming, and immune escape
  • Modifying the local environment to be less conducive to tumor recurrence

Precision Delivery via Catheter and Pump System

We are developing a portable, implantable catheter-pump system to deliver the therapeutic agent directly into the post-surgical cavity, with:

  • Controlled, bi-directional flow for precise drug distribution and local tissue exposure
  • Fluid collection capabilities for real-time monitoring and biomarker analysis
  • Channel-switching functionality to adapt dosing protocols as needed
  • Localized circulation, minimizing drug exposure to non-targeted brain tissue

This delivery platform ensures precision therapy exactly where it’s needed-with minimal systemic toxicity.


Note: These technologies are under development and intended for future clinical use in accordance with applicable regulations.


Together we redefine the landscape of GBM treatments